TSLA
Tesla
-- 236.260 NVDA
NVIDIA
-- 118.530 PLTR
Palantir
-- 87.390 MU
Micron Technology
-- 103.000 INTC
Intel
-- 23.960 
NEWS SUNDAY 12/8
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical benefit rate at the highest dose level. The drug demonstrated a well-tolerated safety profile with manageable neutropenia.
In NHL, cemsidomide monotherapy showed a 38% overall response rate and 19% complete metabolic response rate. Notably, in peripheral T-cell lymphoma, the drug achieved a 44% overall response rate and 25% complete metabolic response rate.
The company is positioning cemsidomide for future development in multiple myeloma combination regimens and various NHL subtypes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment